Adenosine vs Diltiazem for Treatment of SVT in the ED

Phase 4

Recruiting

• Conditions: Supraventricular Tachycardia (SVT)
• Interventions: Drug: adenosine; Drug: diltiazem

• Registration Number: NCT06993038
• Lead Sponsor: Anne E. Zepeski

Brief Summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-04-03
• Study First Submitted QC: 2025-05-19
• Study First Posted: 2025-05-28
• Status Verified: 2025-08
• Study Start: 2025-08-01
• Last Update Submitted: 2025-08-01
• Last Update Posted: 2025-08-07
• Primary Completion: 2026-07
• Study Completion: 2026-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Adult patients (18 years and older)
2. Diagnosis of acute, stable SVT in the emergency department

Exclusion Criteria

1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF</= 40%)
4. Severe bronchoconstrictive lung disease
5. Prior hypersensitivity to study medication
6. Previously enrolled in pilot study
7. Pregnant
8. Incarcerated

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Adenosine	adenosine	-
Diltiazem	diltiazem	-

Primary Outcome Measures

Name	Time	Method
Feasibility outcome	From enrollment to the end of ED encounter (up to 24 hours).	Participants who complete all study procedures (Threshold \>80%)

Trial Locations

Locations (1)

University of Iowa Health Care; 🇺🇸 Iowa City, Iowa, United States